Review
. 2015 Jul;12(10).
doi: 10.1038/nrclinonc.2015.117.

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

Rinath Jeselsohn 1 Gilles Buchwalter 2 Carmine De Angelis 3 Myles Brown 1 Rachel Schiff 3 
Affiliations
  • PMID: 26122181
  •     93 References
  •     119 citations

Abstract

Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, treated with endocrine therapies. However, about 25% of patients with primary disease and almost all patients with metastases will present with or eventually develop endocrine resistance. Despite the magnitude of this clinical challenge, the mechanisms underlying the development of resistance remain largely unknown. In the past 2 years, several studies unveiled gain-of-function mutations in ESR1, the gene encoding the ER, in approximately 20% of patients with metastatic ER-positive disease who received endocrine therapies, such as tamoxifen and aromatase inhibitors. These mutations are clustered in a 'hotspot' within the ligand-binding domain (LBD) of the ER and lead to ligand-independent ER activity that promotes tumour growth, partial resistance to endocrine therapy, and potentially enhanced metastatic capacity; thus, ER LBD mutations might account for a mechanism of acquired endocrine resistance in a substantial fraction of patients with metastatic disease. In general, the absence of detectable ESR1 mutations in patients with treatment-naive disease, and the correlation between the frequency of patients with tumours harbouring these mutations and the number of endocrine treatments received suggest that, under selective treatment pressure, clonal expansion of rare mutant clones occurs, leading to resistance. Preclinical and clinical development of rationale-based novel therapeutic strategies that inhibit these ER mutants has the potential to substantially improve treatment outcomes. We discuss the contribution of ESR1 mutations to the development of acquired resistance to endocrine therapy, and evaluate how mutated ER can be detected and targeted to overcome resistance and improve patient outcomes.

Mutant ras epitopes as targets for cancer vaccines.
S I Abrams, P H Hand, K Y Tsang, J Schlom.
Semin Oncol, 1996 Feb 01; 23(1). PMID: 8607022
Review.
Breast cancer adjuvant endocrine therapy.
Tessa Cigler, Paul E Goss.
Cancer J, 2007 Jul 11; 13(3). PMID: 17620763
Review.
Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.
Mathieu Lupien, Clifford A Meyer, +8 authors, Myles Brown.
Genes Dev, 2010 Oct 05; 24(19). PMID: 20889718    Free PMC article.
Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen.
Amy M Fowler, Natalia Solodin, +3 authors, Elaine T Alarid.
FASEB J, 2004 Jan 14; 18(1). PMID: 14718389
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
José Baselga, Mario Campone, +18 authors, Gabriel N Hortobagyi.
N Engl J Med, 2011 Dec 14; 366(6). PMID: 22149876    Free PMC article.
Highly Cited.
Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
Ines Barone, Yukun Cui, +6 authors, Suzanne A W Fuqua.
Cancer Res, 2009 Jun 03; 69(11). PMID: 19487288    Free PMC article.
Sex hormone receptor repertoire in breast cancer.
Gerald M Higa, Ryan G Fell.
Int J Breast Cancer, 2013 Dec 11; 2013. PMID: 24324894    Free PMC article.
Review.
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
Frederik Holst, Phillip R Stahl, +9 authors, Ronald Simon.
Nat Genet, 2007 Apr 10; 39(5). PMID: 17417639
Highly Cited.
Estrogen receptors in breast carcinogenesis and endocrine therapy.
Bo Huang, Margaret Warner, Jan-Åke Gustafsson.
Mol Cell Endocrinol, 2014 Nov 30; 418 Pt 3. PMID: 25433206
Review.
The renaissance of endocrine therapy in breast cancer.
Nicole Williams, Lyndsay N Harris.
Curr Opin Obstet Gynecol, 2013 Dec 19; 26(1). PMID: 24346127
Review.
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Weiyi Toy, Yang Shen, +15 authors, Sarat Chandarlapaty.
Nat Genet, 2013 Nov 05; 45(12). PMID: 24185512    Free PMC article.
Highly Cited.
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Ken Takezawa, Valentina Pirazzoli, +13 authors, William Pao.
Cancer Discov, 2012 Sep 08; 2(10). PMID: 22956644    Free PMC article.
Highly Cited.
Estrogen receptor interaction with estrogen response elements.
C M Klinge.
Nucleic Acids Res, 2001 Jul 14; 29(14). PMID: 11452016    Free PMC article.
Highly Cited. Review.
Clonal evolution in breast cancer revealed by single nucleus genome sequencing.
Yong Wang, Jill Waters, +13 authors, Nicholas E Navin.
Nature, 2014 Aug 01; 512(7513). PMID: 25079324    Free PMC article.
Highly Cited.
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.
Albana Gattelli, Ivan Nalvarte, +9 authors, Nancy E Hynes.
EMBO Mol Med, 2013 Jul 23; 5(9). PMID: 23868506    Free PMC article.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma.
E F McClay, M T McClay, +2 authors, P J Winski.
Melanoma Res, 2001 Jul 27; 11(3). PMID: 11468521
Breast cancer intratumor genetic heterogeneity: causes and implications.
Charlotte K Y Ng, Helen N Pemberton, Jorge S Reis-Filho.
Expert Rev Anticancer Ther, 2012 Oct 04; 12(8). PMID: 23030222
Review.
Clonal evolution in cancer.
Mel Greaves, Carlo C Maley.
Nature, 2012 Jan 20; 481(7381). PMID: 22258609    Free PMC article.
Highly Cited. Review.
The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?
Stephen R D Johnston, Belinda Yeo.
Curr Oncol Rep, 2014 Jan 07; 16(1). PMID: 24390724
Review.
Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.
I Barone, D Iacopetta, +5 authors, S A W Fuqua.
Oncogene, 2010 Jan 27; 29(16). PMID: 20101208    Free PMC article.
Liquid biopsies: genotyping circulating tumor DNA.
Luis A Diaz, Alberto Bardelli.
J Clin Oncol, 2014 Jan 23; 32(6). PMID: 24449238    Free PMC article.
Highly Cited. Review.
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.
Cinzia Giordano, Yukun Cui, +4 authors, Suzanne A W Fuqua.
Breast Cancer Res Treat, 2009 Feb 12; 119(1). PMID: 19205871    Free PMC article.
In vivo amplification of the androgen receptor gene and progression of human prostate cancer.
T Visakorpi, E Hyytinen, +7 authors, O P Kallioniemi.
Nat Genet, 1995 Apr 01; 9(4). PMID: 7795646
Highly Cited.
Estrogen receptors and human disease: an update.
Katherine A Burns, Kenneth S Korach.
Arch Toxicol, 2012 Jun 01; 86(10). PMID: 22648069    Free PMC article.
Review.
Digital PCR.
B Vogelstein, K W Kinzler.
Proc Natl Acad Sci U S A, 1999 Aug 04; 96(16). PMID: 10430926    Free PMC article.
Highly Cited.
Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer.
N Roodi, L R Bailey, +4 authors, F F Parl.
J Natl Cancer Inst, 1995 Mar 15; 87(6). PMID: 7861463
Progress in endocrine approaches to the treatment and prevention of breast cancer.
Ifeyinwa Obiorah, V Craig Jordan.
Maturitas, 2011 Oct 11; 70(4). PMID: 21982237    Free PMC article.
Review.
Nuclear receptor minireview series.
J M Olefsky.
J Biol Chem, 2001 Jul 19; 276(40). PMID: 11459855
Review.
Biological determinants of endocrine resistance in breast cancer.
Elizabeth A Musgrove, Robert L Sutherland.
Nat Rev Cancer, 2009 Aug 25; 9(9). PMID: 19701242
Highly Cited. Review.
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.
Osama E Rahma, J Michael Hamilton, +5 authors, Samir N Khleif.
J Transl Med, 2014 Feb 26; 12. PMID: 24565030    Free PMC article.
Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.
Sakineh Abbasi, Mina Rasouli, Mehrnaz Nouri, Samira Kalbasi.
Int J Clin Exp Med, 2012 Dec 14; 6(1). PMID: 23236557    Free PMC article.
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
S A Fuqua, C Wiltschke, +8 authors, D C Allred.
Cancer Res, 2000 Aug 17; 60(15). PMID: 10945602
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.
Q X Zhang, A Borg, +2 authors, S A Fuqua.
Cancer Res, 1997 Apr 01; 57(7). PMID: 9102207
Highly Cited.
Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.
Stephen X Skapek, James R Anderson, +8 authors, R Beverly Raney.
Pediatr Blood Cancer, 2013 Jan 03; 60(7). PMID: 23281268    Free PMC article.
The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.
Kathleen Conway, Eloise Parrish, +7 authors, Robert C Millikan.
Breast Cancer Res, 2005 Nov 11; 7(6). PMID: 16280033    Free PMC article.
The molecular profile of luminal B breast cancer.
Chad J Creighton.
Biologics, 2012 Sep 08; 6. PMID: 22956860    Free PMC article.
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li, Dong Shen, +52 authors, Matthew J Ellis.
Cell Rep, 2013 Sep 24; 4(6). PMID: 24055055    Free PMC article.
Highly Cited.
Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
Samuel W Brady, Jian Zhang, +2 authors, Dihua Yu.
Molecular cancer therapeutics, 2013 Nov 20; 13(1). PMID: 24249715    Free PMC article.
Molecular basis of agonism and antagonism in the oestrogen receptor.
A M Brzozowski, A C Pike, +7 authors, M Carlquist.
Nature, 1997 Oct 24; 389(6652). PMID: 9338790
Highly Cited.
Detection of ultra-rare mutations by next-generation sequencing.
Michael W Schmitt, Scott R Kennedy, +3 authors, Lawrence A Loeb.
Proc Natl Acad Sci U S A, 2012 Aug 03; 109(36). PMID: 22853953    Free PMC article.
Highly Cited.
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Jing Peng, Surojeet Sengupta, V Craig Jordan.
Anticancer Agents Med Chem, 2009 Jun 13; 9(5). PMID: 19519291    Free PMC article.
Review.
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Richard S Finn, Judy Dering, +9 authors, Dennis J Slamon.
Breast Cancer Res, 2009 Oct 31; 11(5). PMID: 19874578    Free PMC article.
Highly Cited.
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.
Suzanne A W Fuqua, Guowei Gu, Yassine Rechoum.
Breast Cancer Res Treat, 2014 Feb 04; 144(1). PMID: 24487689    Free PMC article.
Review.
Genetic heterogeneity and cancer drug resistance.
Nicholas C Turner, Jorge S Reis-Filho.
Lancet Oncol, 2012 Apr 04; 13(4). PMID: 22469128
Highly Cited.
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.
S C Drury, S Detre, +10 authors, M Dowsett.
Endocr Relat Cancer, 2011 Jul 08; 18(5). PMID: 21734071
Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases.
Laurien D C Hoefnagel, Cathy B Moelans, +12 authors, Paul J van Diest.
Cancer, 2012 Mar 15; 118(20). PMID: 22415862
Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
Helena A Yu, Gregory J Riely, Christine M Lovly.
Clin Cancer Res, 2014 Oct 12; 20(23). PMID: 25303979    Free PMC article.
Review.
Hypersensitive K303R oestrogen receptor-alpha variant not found in invasive carcinomas.
Michael P A Davies, Penny A O'Neill, Helen Innes, D Ross Sibson.
Breast Cancer Res, 2005 Jan 12; 7(1). PMID: 15642159    Free PMC article.
A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer.
Selma Esseghir, S Katrina Todd, +4 authors, Clare M Isacke.
Cancer Res, 2007 Dec 20; 67(24). PMID: 18089803
Use of SERMs for treatment in postmenopausal women.
Joann V Pinkerton, Semara Thomas.
J Steroid Biochem Mol Biol, 2014 Jan 01; 142. PMID: 24373794
Review.
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer.
Matthew H Herynk, Irma Parra, +4 authors, Suzanne A W Fuqua.
Clin Cancer Res, 2007 Jun 05; 13(11). PMID: 17545528    Free PMC article.
Pure oestrogen antagonists for the treatment of advanced breast cancer.
Anthony Howell.
Endocr Relat Cancer, 2006 Sep 07; 13(3). PMID: 16954425
Review.
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Rachel Schiff, Suleiman A Massarweh, +4 authors, C Kent Osborne.
Cancer Chemother Pharmacol, 2005 Nov 08; 56 Suppl 1. PMID: 16273359
Review.
Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.
G Lazennec, T R Ediger, +2 authors, B S Katzenellenbogen.
Mol Endocrinol, 1997 Aug 01; 11(9). PMID: 9259327
New strategies in estrogen receptor-positive breast cancer.
Stephen R D Johnston.
Clin Cancer Res, 2010 Mar 25; 16(7). PMID: 20332324
Review.
No hypersensitive estrogen receptor-alpha mutation (K303R) in Japanese breast carcinomas.
Eriko Tokunaga, Yasue Kimura, Yoshihiko Maehara.
Breast Cancer Res Treat, 2004 Mar 18; 84(3). PMID: 15026626
Elusive extranuclear estrogen receptors in breast cancer.
Ellis R Levin.
Clin Cancer Res, 2012 Jan 05; 18(1). PMID: 22215901    Free PMC article.
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, +16 authors, Pasi A Jänne.
Science, 2007 Apr 28; 316(5827). PMID: 17463250
Highly Cited.
Absence of the K303R estrogen receptor α mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment.
Chiara Ghimenti, Maurizia Mello-Grand, +2 authors, Giovanna Chiorino.
Exp Ther Med, 2010 Nov 01; 1(6). PMID: 22993622    Free PMC article.
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Rachel Schiff, Suleiman Massarweh, Jiang Shou, C Kent Osborne.
Clin Cancer Res, 2003 Jan 23; 9(1 Pt 2). PMID: 12538499
Review.
Detection and quantification of rare mutations with massively parallel sequencing.
Isaac Kinde, Jian Wu, +2 authors, Bert Vogelstein.
Proc Natl Acad Sci U S A, 2011 May 19; 108(23). PMID: 21586637    Free PMC article.
Highly Cited.
Estrogen receptor mutations in tamoxifen-resistant breast cancer.
P S Karnik, S Kulkarni, +2 authors, R M Bukowski.
Cancer Res, 1994 Jan 15; 54(2). PMID: 8275466
Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network.
Nature, 2012 Sep 25; 490(7418). PMID: 23000897    Free PMC article.
Highly Cited.
D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.
Keren Merenbakh-Lamin, Noa Ben-Baruch, +11 authors, Ido Wolf.
Cancer Res, 2013 Nov 13; 73(23). PMID: 24217577
Highly Cited.
Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1.
Ying Wang, David M Lonard, +14 authors, Bert W O'Malley.
Cancer Res, 2014 Jan 07; 74(5). PMID: 24390736    Free PMC article.
Highly Cited.
WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration.
Mary A Dwyer, James D Joseph, +5 authors, Donald P McDonnell.
Cancer Res, 2010 Sep 28; 70(22). PMID: 20870744    Free PMC article.
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.
L-Y Huw, C O'Brien, +7 authors, M R Lackner.
Oncogenesis, 2013 Dec 25; 2. PMID: 24366379    Free PMC article.
Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.
Min Yu, Aditya Bardia, +21 authors, Daniel A Haber.
Science, 2014 Jul 12; 345(6193). PMID: 25013076    Free PMC article.
Highly Cited.
Next-generation DNA sequencing.
Jay Shendure, Hanlee Ji.
Nat Biotechnol, 2008 Oct 11; 26(10). PMID: 18846087
Highly Cited.
Acquired resistance to drugs targeting receptor tyrosine kinases.
Steven A Rosenzweig.
Biochem Pharmacol, 2012 Jan 10; 83(8). PMID: 22227013    Free PMC article.
Review.
Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.
Fei Yan, Yang Yu, +7 authors, David M Lonard.
PLoS One, 2014 Apr 20; 9(4). PMID: 24743578    Free PMC article.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Angelo Di Leo, Guy Jerusalem, +12 authors, Miguel Martin.
J Clin Oncol, 2010 Sep 22; 28(30). PMID: 20855825
Highly Cited.
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Dan R Robinson, Yi-Mi Wu, +22 authors, Arul M Chinnaiyan.
Nat Genet, 2013 Nov 05; 45(12). PMID: 24185510    Free PMC article.
Highly Cited.
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.
Rinath Jeselsohn, Roman Yelensky, +28 authors, Vincent A Miller.
Clin Cancer Res, 2014 Jan 09; 20(7). PMID: 24398047    Free PMC article.
Highly Cited.
Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action.
Stefan Glück.
Clin Breast Cancer, 2013 Dec 21; 14(2). PMID: 24355138
Review.
In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy.
R Masson, O Lefebvre, +9 authors, M C Rio.
J Cell Biol, 1998 Apr 29; 140(6). PMID: 9508784    Free PMC article.
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast.
Salvatore Piscuoglio, Charlotte K Y Ng, +10 authors, Jorge S Reis-Filho.
Mol Oncol, 2014 Jul 22; 8(8). PMID: 25041824    Free PMC article.
Mechanisms of endocrine resistance in breast cancer.
C Kent Osborne, Rachel Schiff.
Annu Rev Med, 2010 Oct 05; 62. PMID: 20887199    Free PMC article.
Highly Cited. Review.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Absence of ESR1 amplification in a series of breast cancers.
José Adélaïde, Pascal Finetti, +6 authors, Max Chaffanet.
Int J Cancer, 2008 Sep 26; 123(12). PMID: 18816632
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses.
Kendall W Nettles, John B Bruning, +11 authors, Geoffrey L Greene.
Nat Chem Biol, 2008 Mar 18; 4(4). PMID: 18344977    Free PMC article.
Improving T cell responses to modified peptides in tumor vaccines.
Jonathan D Buhrman, Jill E Slansky.
Immunol Res, 2012 Sep 01; 55(1-3). PMID: 22936035    Free PMC article.
Review.
Estrogen receptor pathways to AP-1.
P J Kushner, D A Agard, +4 authors, P Webb.
J Steroid Biochem Mol Biol, 2001 Feb 13; 74(5). PMID: 11162939
Highly Cited. Review.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
Saori Tomita, Zhenhuan Zhang, +4 authors, Hirotaka Iwase.
Cancer Sci, 2009 Mar 27; 100(6). PMID: 19320640
Considerations for digital PCR as an accurate molecular diagnostic tool.
Jim F Huggett, Simon Cowen, Carole A Foy.
Clin Chem, 2014 Oct 24; 61(1). PMID: 25338683
Highly Cited. Review.
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
Aaron M Newman, Scott V Bratman, +11 authors, Maximilian Diehn.
Nat Med, 2014 Apr 08; 20(5). PMID: 24705333    Free PMC article.
Highly Cited.
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
John F R Robertson, C Kent Osborne, +10 authors, Charles Morris.
Cancer, 2003 Jul 23; 98(2). PMID: 12872340
Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
D Dodwell, A Wardley, S Johnston.
Breast, 2006 Mar 01; 15(5). PMID: 16504510
Review.
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction.
K E Carlson, I Choi, +2 authors, J A Katzenellenbogen.
Biochemistry, 1997 Dec 16; 36(48). PMID: 9398213
The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer.
Melanie Spears, John Bartlett.
Expert Opin Ther Targets, 2009 May 22; 13(6). PMID: 19456271
Review.
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.
Jamunarani Veeraraghavan, Ying Tan, +11 authors, Xiao-Song Wang.
Nat Commun, 2014 Aug 08; 5. PMID: 25099679    Free PMC article.
Development of Companion Diagnostics.
David A Mankoff, Christine E Edmonds, Michael D Farwell, Daniel A Pryma.
Semin Nucl Med, 2015 Dec 22; 46(1). PMID: 26687857    Free PMC article.
Review.
Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer.
Kazushi Inoue, Elizabeth A Fry.
Genet Epigenet, 2015 Dec 23; 7. PMID: 26692764    Free PMC article.
Review.
Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.
Yunus A Luqmani, Nada Alam-Eldin.
Med Princ Pract, 2016 Feb 06; 25 Suppl 2. PMID: 26849149    Free PMC article.
Review.
Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer.
Jaime Matta, Luisa Morales, +6 authors, Erick Suárez.
PLoS One, 2016 Apr 01; 11(3). PMID: 27032101    Free PMC article.
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.
Costanza Paoletti, Jose M Larios, +13 authors, Daniel F Hayes.
Mol Oncol, 2016 May 15; 10(7). PMID: 27178224    Free PMC article.
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
Rinath Jeselsohn, William T Barry, +10 authors, Luca Malorni.
Clin Cancer Res, 2016 Nov 01; 22(23). PMID: 27185372    Free PMC article.
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
Libero Santarpia, Giulia Bottai, +3 authors, Lajos Pusztai.
Oncologist, 2016 Jul 08; 21(9). PMID: 27384237    Free PMC article.
Review.
Metastatic breast cancer: The Odyssey of personalization.
A Sonnenblick, N Pondé, M Piccart.
Mol Oncol, 2016 Jul 20; 10(8). PMID: 27430154    Free PMC article.
Review.
A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol.
Milagros Gonzalez-Rivera, Antoni C Picornell, Enrique L Alvarez, Miguel Martin.
JMIR Res Protoc, 2016 Aug 18; 5(3). PMID: 27531554    Free PMC article.
Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care-Insured Women, New York State, 2012-2014.
Victoria L Wagner, Wei Jing, +3 authors, Foster C Gesten.
Prev Chronic Dis, 2016 Sep 02; 13. PMID: 27584876    Free PMC article.
Antiestrogens: structure-activity relationships and use in breast cancer treatment.
T Traboulsi, M El Ezzy, J L Gleason, S Mader.
J Mol Endocrinol, 2016 Oct 13; 58(1). PMID: 27729460    Free PMC article.
Review.
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Emily K Law, Anieta M Sieuwerts, +12 authors, Reuben S Harris.
Sci Adv, 2016 Oct 13; 2(10). PMID: 27730215    Free PMC article.
Highly Cited.
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.
Laurence Lousberg, Joëlle Collignon, Guy Jerusalem.
Ther Adv Med Oncol, 2016 Nov 02; 8(6). PMID: 27800032    Free PMC article.
Review.
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Florian Clatot, Anne Perdrix, +21 authors, Frédéric Di Fiore.
Oncotarget, 2016 Nov 02; 7(46). PMID: 27801670    Free PMC article.
Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials.
Francisco Beca, Andrew H Beck.
PLoS Med, 2016 Dec 07; 13(12). PMID: 27923047    Free PMC article.
Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer.
Xi Zhang, Nadia Harbeck, Udo Jeschke, Sophie Doisneau-Sixou.
J Cancer Res Clin Oncol, 2016 Dec 28; 143(7). PMID: 28025696
Review.
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Celine Lefebvre, Thomas Bachelot, +31 authors, Fabrice André.
PLoS Med, 2016 Dec 28; 13(12). PMID: 28027327    Free PMC article.
Highly Cited.
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
Angela Toss, Marta Venturelli, +3 authors, Laura Cortesi.
Int J Mol Sci, 2017 Jan 06; 18(1). PMID: 28054957    Free PMC article.
Review.
ESR1 mutations in breast cancer.
Florian Clatot, Laetitia Augusto, Frédéric Di Fiore.
Aging (Albany NY), 2017 Jan 29; 9(1). PMID: 28130553    Free PMC article.
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Ami N Shah, Massimo Cristofanilli.
Curr Treat Options Oncol, 2017 Feb 16; 18(1). PMID: 28197838
Review.
Progress with palbociclib in breast cancer: latest evidence and clinical considerations.
Andrea Rocca, Alessio Schirone, +5 authors, Daniele Andreis.
Ther Adv Med Oncol, 2017 Feb 17; 9(2). PMID: 28203301    Free PMC article.
Review.
Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.
Laura J Tafe.
Virchows Arch, 2017 Mar 11; 471(2). PMID: 28280929
Review.
Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer.
Tomas Reinert, Everardo D Saad, Carlos H Barrios, José Bines.
Front Oncol, 2017 Apr 01; 7. PMID: 28361033    Free PMC article.
Review.
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.
I Bado, Z Gugala, S A W Fuqua, X H-F Zhang.
Oncogene, 2017 Apr 04; 36(32). PMID: 28368409    Free PMC article.
Review.
FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis.
Feng Xie, Ke Jin, +13 authors, Long Zhang.
Nat Commun, 2017 Apr 27; 8. PMID: 28443643    Free PMC article.
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
Rinath Jeselsohn, MacIntosh Cornwell, +20 authors, Myles Brown.
Proc Natl Acad Sci U S A, 2017 May 17; 114(22). PMID: 28507152    Free PMC article.
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Amir Bahreini, Zheqi Li, +11 authors, Steffi Oesterreich.
Breast Cancer Res, 2017 May 26; 19(1). PMID: 28535794    Free PMC article.
Highly Cited.
Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients.
Xi Zhang, Simone Hofmann, +3 authors, Sophie Sixou.
Int J Mol Sci, 2017 Jun 21; 18(6). PMID: 28632174    Free PMC article.
Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells.
Carmela Paolillo, Zhaomei Mu, +7 authors, Paolo Fortina.
Clin Cancer Res, 2017 Jul 07; 23(20). PMID: 28679775    Free PMC article.
A Review of Fulvestrant in Breast Cancer.
Mark R Nathan, Peter Schmid.
Oncol Ther, 2017 Jul 07; 5(1). PMID: 28680952    Free PMC article.
Review.
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Jamunarani Veeraraghavan, Carmine De Angelis, +5 authors, Rachel Schiff.
Breast, 2017 Jul 09; 34 Suppl 1. PMID: 28687441    Free PMC article.
Review.
The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells.
Penn Muluhngwi, Negin Alizadeh-Rad, +2 authors, Carolyn M Klinge.
Sci Rep, 2017 Jul 14; 7(1). PMID: 28701793    Free PMC article.
Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis.
Zongbi Yi, Fei Ma, +9 authors, Binghe Xu.
Sci Rep, 2017 Jul 22; 7(1). PMID: 28729728    Free PMC article.
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.
Yuechao Zhao, Mary J Laws, +12 authors, Benita S Katzenellenbogen.
Cancer Res, 2017 Sep 15; 77(20). PMID: 28904064    Free PMC article.
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
Iman Doostan, Cansu Karakas, +7 authors, Khandan Keyomarsi.
Clin Cancer Res, 2017 Sep 28; 23(23). PMID: 28947566    Free PMC article.
18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer.
Kelley Salem, Manoj Kumar, +4 authors, Amy M Fowler.
Radiology, 2017 Sep 29; 286(3). PMID: 28956736    Free PMC article.
Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Zheqi Li, Kevin M Levine, +5 authors, Adrian V Lee.
Endocrinology, 2017 Oct 14; 159(1). PMID: 29029116    Free PMC article.
Metastatic breast cancer: Endocrine therapy landscape reshaped.
Mohamad Adham Salkeni, Samantha June Hall.
Avicenna J Med, 2017 Nov 10; 7(4). PMID: 29119080    Free PMC article.
Review.
MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells.
Min-Ho Lee, Dahae Koh, +7 authors, Mi-Ock Lee.
Autophagy, 2017 Nov 14; 14(5). PMID: 29130361    Free PMC article.
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
Derek F Amanatullah, John S Tamaresis, +8 authors, Bonnie L King.
Breast Cancer Res, 2017 Nov 17; 19(1). PMID: 29141657    Free PMC article.
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Lesley-Ann Martin, Ricardo Ribas, +25 authors, Mitch Dowsett.
Nat Commun, 2017 Dec 02; 8(1). PMID: 29192207    Free PMC article.
Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.
Costanza Paoletti, Andi K Cani, +24 authors, Scott A Tomlins.
Cancer Res, 2017 Dec 14; 78(4). PMID: 29233927    Free PMC article.
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.
Cristina Guarducci, Martina Bonechi, +5 authors, Ilenia Migliaccio.
Breast Care (Basel), 2017 Dec 14; 12(5). PMID: 29234249    Free PMC article.
Review.
Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.
Vineet K Dhiman, Michael J Bolt, Kevin P White.
Nat Rev Genet, 2017 Dec 28; 19(3). PMID: 29279606
Review.
Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.
Shanhang Jia, Mark T Miedel, +13 authors, Andrew M Stern.
Oncology, 2018 Jan 08; 94(3). PMID: 29306943    Free PMC article.
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Adam M Brufsky, Maura N Dickler.
Oncologist, 2018 Jan 21; 23(5). PMID: 29352052    Free PMC article.
Review.
A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen.
Kang Wang, Jie Li, +3 authors, Hong-Yuan Li.
Sci Rep, 2018 Feb 18; 8(1). PMID: 29453409    Free PMC article.
A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response.
Marcella Regina Cardoso, Juliana Carvalho Santos, +3 authors, Sophie Françoise Mauricette Derchain.
Int J Mol Sci, 2018 Feb 22; 19(2). PMID: 29466297    Free PMC article.
Review.
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
Ben O'Leary, Sarah Hrebien, +10 authors, Nicholas C Turner.
Nat Commun, 2018 Mar 03; 9(1). PMID: 29497091    Free PMC article.
Highly Cited.
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.
Laura Lupini, Anna Moretti, +6 authors, Massimo Negrini.
Sci Rep, 2018 Mar 14; 8(1). PMID: 29531247    Free PMC article.
Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.
Linjie Zhao, Shuang Huang, +16 authors, Shengtao Zhou.
Proc Natl Acad Sci U S A, 2018 Mar 30; 115(16). PMID: 29592953    Free PMC article.
Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
Julia Böck, Silke Appenzeller, +8 authors, Thomas Haaf.
Int J Cancer, 2018 Apr 17; 143(6). PMID: 29659014    Free PMC article.
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.
John A Katzenellenbogen, Christopher G Mayne, +2 authors, Sarat Chandarlapaty.
Nat Rev Cancer, 2018 Apr 18; 18(6). PMID: 29662238    Free PMC article.
Highly Cited. Review.
Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.
Tomás Reinert, Rodrigo Gonçalves, José Bines.
Curr Treat Options Oncol, 2018 Apr 19; 19(5). PMID: 29666928
Review.
Chromatin reprogramming in breast cancer.
Erin E Swinstead, Ville Paakinaho, Gordon L Hager.
Endocr Relat Cancer, 2018 Apr 26; 25(7). PMID: 29692347    Free PMC article.
Review.
Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer.
Senthil Rajappa, J Bajpai, +8 authors, S Aggarwal.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721481    Free PMC article.
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.
Sasha M Pejerrey, Derek Dustin, +3 authors, Suzanne A W Fuqua.
Horm Cancer, 2018 May 08; 9(4). PMID: 29736566
Review.
Estrogen Receptors: New Directions in the New Millennium.
Sylvia C Hewitt, Kenneth S Korach.
Endocr Rev, 2018 Jun 15; 39(5). PMID: 29901737    Free PMC article.
Highly Cited. Review.
Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
Tengfei Xiao, Wei Li, +18 authors, Myles Brown.
Proc Natl Acad Sci U S A, 2018 Jul 11; 115(31). PMID: 29987050    Free PMC article.
Disrupting a negative feedback loop drives endocrine therapy-resistant breast cancer.
Charles E Foulds.
Proc Natl Acad Sci U S A, 2018 Aug 08; 115(33). PMID: 30082387    Free PMC article.
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer.
Yanan Kuang, Bilal Siddiqui, +14 authors, Rinath Jeselsohn.
NPJ Breast Cancer, 2018 Aug 08; 4. PMID: 30083595    Free PMC article.
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.
Tanya T Kwan, Aditya Bardia, +15 authors, Shyamala Maheswaran.
Cancer Discov, 2018 Aug 15; 8(10). PMID: 30104333    Free PMC article.
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Claudia Busonero, Stefano Leone, Fabrizio Bianchi, Filippo Acconcia.
Cell Oncol (Dordr), 2018 Sep 06; 41(6). PMID: 30182339
Predictive markers of endocrine response in breast cancer.
Duniya Mosly, Arran Turnbull, +2 authors, Simon Langdon.
World J Exp Med, 2018 Sep 08; 8(1). PMID: 30191138    Free PMC article.
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence.
Andrea Rocca, Roberta Maltoni, +2 authors, Daniele Andreis.
Cancer Manag Res, 2018 Sep 15; 10. PMID: 30214302    Free PMC article.
Review.
The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer.
Yangfan Du, Na Li, +2 authors, Shunchao Yan.
Onco Targets Ther, 2018 Oct 03; 11. PMID: 30275706    Free PMC article.
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Xu Liang, Adrien Briaux, +12 authors, Céline Callens.
J Hematol Oncol, 2018 Oct 12; 11(1). PMID: 30305115    Free PMC article.
Moving Breast Cancer Therapy up a Notch.
Erik W J Mollen, Jonathan Ient, +4 authors, Marc A G G Vooijs.
Front Oncol, 2018 Dec 06; 8. PMID: 30515368    Free PMC article.
Review.
Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant Activity.
David K Lung, Jay W Warrick, +4 authors, Elaine T Alarid.
Endocrinology, 2019 Sep 11; 160(10). PMID: 31504407    Free PMC article.
ERα-targeted endocrine therapy, resistance and the role of GPER.
Richard A Pepermans, Eric R Prossnitz.
Steroids, 2019 Sep 14; 152. PMID: 31518595    Free PMC article.
Review.
Signaling Complexity Measured by Shannon Entropy and Its Application in Personalized Medicine.
Alessandra J Conforte, Jack Adam Tuszynski, Fabricio Alves Barbosa da Silva, Nicolas Carels.
Front Genet, 2019 Nov 07; 10. PMID: 31695721    Free PMC article.
Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study.
Xuelu Li, Jiawei Lu, +3 authors, Man Li.
Transl Oncol, 2019 Dec 27; 13(2). PMID: 31877464    Free PMC article.
Mutational landscape implicates epithelial-mesenchymal transition gene TGF-β2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma.
Ling Shen, Liangli Hong, +2 authors, Ruiqin Mai.
Int J Clin Exp Pathol, 2020 Jan 15; 12(3). PMID: 31933910    Free PMC article.
Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.
Eloi R Verrier, Amélie Weiss, +13 authors, Thomas F Baumert.
Gut, 2019 Mar 06; 69(1). PMID: 30833451    Free PMC article.
Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health.
Balkees Abderrahman, V Craig Jordan.
Endocrinology, 2018 Jun 23; 159(8). PMID: 29931061    Free PMC article.
Review.
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy.
Irene De Santo, Amelia McCartney, +2 authors, Luca Malorni.
Cancers (Basel), 2019 Dec 05; 11(12). PMID: 31795152    Free PMC article.
Review.
Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer.
Wenzhen Zhu, Chongyang Ren, +3 authors, Ning Liao.
Onco Targets Ther, 2020 Feb 06; 13. PMID: 32021303    Free PMC article.
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Adi Zundelevich, Maya Dadiani, +14 authors, Einav Nili Gal-Yam.
Breast Cancer Res, 2020 Feb 06; 22(1). PMID: 32014063    Free PMC article.
Dynamics Insights Into the Gain of Flexibility by Helix-12 in ESR1 as a Mechanism of Resistance to Drugs in Breast Cancer Cell Lines.
Abbas Khan, Ashfaq-Ur-Rehman, +7 authors, Dong-Qing Wei.
Front Mol Biosci, 2020 Feb 11; 6. PMID: 32039233    Free PMC article.
Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
Jin Zhang, Qianying Wang, +3 authors, Zhengmao Zhu.
Cell Mol Life Sci, 2019 Sep 01; 77(4). PMID: 31471681
Review.
Molecular Barcode Sequencing of the Whole Ligand Binding Domain of the ESR1 Gene in Cell-Free DNA from Patients with Metastatic Breast Cancer.
Nanae Masunaga, Naofumi Kagara, +8 authors, Shinzaburo Noguchi.
Transl Oncol, 2020 Feb 28; 13(3). PMID: 32105989    Free PMC article.
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Pushpinder Kaur, Tania B Porras, +2 authors, Julie E Lang.
Sci Rep, 2019 Feb 08; 9(1). PMID: 30728399    Free PMC article.
Modeling the Effect of the Metastatic Microenvironment on Phenotypes Conferred by Estrogen Receptor Mutations Using a Human Liver Microphysiological System.
Mark T Miedel, Dillon C Gavlock, +3 authors, Andrew M Stern.
Sci Rep, 2019 Jun 07; 9(1). PMID: 31171849    Free PMC article.
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Sarah Sammons, Noah S Kornblum, Kimberly L Blackwell.
Target Oncol, 2018 Aug 24; 14(1). PMID: 30136059    Free PMC article.
Review.
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
Ben O'Leary, Rosalind J Cutts, +10 authors, Nicholas C Turner.
Cancer Discov, 2018 Sep 13; 8(11). PMID: 30206110    Free PMC article.
Highly Cited.
Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Distinct Entity Characterized by Recurrent NCOA2/3 Gene Fusions.
Brendan C Dickson, Timothy J Childs, +4 authors, Cristina R Antonescu.
Am J Surg Pathol, 2018 Oct 03; 43(2). PMID: 30273195    Free PMC article.
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.
Zbyslaw Sondka, Sally Bamford, +3 authors, Simon A Forbes.
Nat Rev Cancer, 2018 Oct 08; 18(11). PMID: 30293088    Free PMC article.
Highly Cited. Review.
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.
Sarah Croessmann, Luigi Formisano, +13 authors, Carlos L Arteaga.
Clin Cancer Res, 2018 Oct 14; 25(1). PMID: 30314968    Free PMC article.
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
Kunihiko Hinohara, Hua-Jun Wu, +25 authors, Kornelia Polyak.
Cancer Cell, 2018 Nov 26; 34(6). PMID: 30472020    Free PMC article.
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Elena Lopez-Knowles, Alex Pearson, +11 authors, Mitch Dowsett.
Br J Cancer, 2018 Dec 20; 120(2). PMID: 30563991    Free PMC article.
Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Jingyu Liu, Jing Li, +5 authors, Quchang Ouyang.
J Transl Med, 2019 Jan 17; 17(1). PMID: 30646914    Free PMC article.
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Luigi Formisano, Yao Lu, +28 authors, Carlos L Arteaga.
Nat Commun, 2019 Mar 28; 10(1). PMID: 30914635    Free PMC article.
Highly Cited.
Translating insights into tumor evolution to clinical practice: promises and challenges.
Matthew W Fittall, Peter Van Loo.
Genome Med, 2019 Mar 31; 11(1). PMID: 30925887    Free PMC article.
Review.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Lorenzo Rossi, Chiara Biagioni, +17 authors, Luca Malorni.
Breast Cancer Res, 2019 May 31; 21(1). PMID: 31142370    Free PMC article.
The microcosmos of intratumor heterogeneity: the space-time of cancer evolution.
Michalina Janiszewska.
Oncogene, 2019 Dec 01; 39(10). PMID: 31784650    Free PMC article.
Review.
Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
José Pérez-Garcia, Javier Cortés, Otto Metzger Filho.
Oncologist, 2018 Dec 24; 24(8). PMID: 30578311    Free PMC article.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Kaitlyn J Andreano, Suzanne E Wardell, +15 authors, John D Norris.
Breast Cancer Res Treat, 2020 Mar 05; 180(3). PMID: 32130619    Free PMC article.
Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer.
Amy M Fowler, Kelley Salem, +6 authors, Aparna M Mahajan.
Horm Cancer, 2020 Jan 17; 11(2). PMID: 31942683    Free PMC article.
Acetylation of histone H3K27 signals the transcriptional elongation for estrogen receptor alpha.
Yujing Gao, Lijia Chen, +16 authors, Qin Feng.
Commun Biol, 2020 Apr 09; 3(1). PMID: 32265480    Free PMC article.
Overcoming Endocrine Resistance in Breast Cancer.
Ariella B Hanker, Dhivya R Sudhan, Carlos L Arteaga.
Cancer Cell, 2020 Apr 15; 37(4). PMID: 32289273    Free PMC article.
Review.
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
Tomás Reinert, Susana Ramalho, +13 authors, Marcia Silveira Graudenz.
Front Oncol, 2020 Apr 21; 10. PMID: 32309212    Free PMC article.
Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer.
Rui Chen, Shipeng Guo, +7 authors, Shengchun Liu.
Int J Oncol, 2020 Apr 23; 56(4). PMID: 32319562    Free PMC article.
Ribonuclease H2 Subunit A impacts invasiveness and chemoresistance resulting in poor survivability of breast cancer in ER dependent manner.
Jianjiang Shen, Sen Lin, Lin Liu, Chenying Wang.
Am J Transl Res, 2020 Jun 09; 12(5). PMID: 32509219    Free PMC article.
Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer.
Hao Liao, Huiping Li.
Cancer Manag Res, 2020 Jun 18; 12. PMID: 32547192    Free PMC article.
Review.
Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
Annamaria Salvati, Valerio Gigantino, +8 authors, Giorgio Giurato.
Int J Mol Sci, 2020 Jun 11; 21(11). PMID: 32517194    Free PMC article.
Review.
The Network of Angiotensin Receptors in Breast Cancer.
Filippo Acconcia.
Cells, 2020 May 31; 9(6). PMID: 32471115    Free PMC article.
Review.
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Young K Chae, Fangxin Hong, +19 authors, Keith T Flaherty.
J Clin Oncol, 2020 May 29; 38(21). PMID: 32463741    Free PMC article.
MAGPEL: an autoMated pipeline for inferring vAriant-driven Gene PanEls from the full-length biomedical literature.
Nafiseh Saberian, Adib Shafi, Azam Peyvandipour, Sorin Draghici.
Sci Rep, 2020 Jul 25; 10(1). PMID: 32703994    Free PMC article.
Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.
Aradhana Rani, Justin Stebbing, Georgios Giamas, John Murphy.
Front Endocrinol (Lausanne), 2019 Jun 11; 10. PMID: 31178825    Free PMC article.
Highly Cited. Review.
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li Li, Ling Lin, +6 authors, Xiao-Song Wang.
Breast Cancer Res, 2020 Aug 11; 22(1). PMID: 32771039    Free PMC article.
Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Junjian Wang, Zhijian Duan, +10 authors, Hong-Wu Chen.
Cancer Lett, 2016 May 11; 378(2). PMID: 27164560    Free PMC article.
Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma.
Elizabeth H Stover, Colleen Feltmate, +3 authors, Panagiotis A Konstantinopoulos.
JCO Precis Oncol, 2018 Jan 01; 2018. PMID: 30828692    Free PMC article.
Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil.
Tomás Reinert, Guilherme Portela Coelho, +5 authors, Marcia Silveira Graudenz.
J Oncol, 2019 Sep 13; 2019. PMID: 31511774    Free PMC article.
Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.
Claudia Koch, Andra Kuske, +28 authors, Klaus Pantel.
EMBO Mol Med, 2020 Jul 16; 12(9). PMID: 32667137    Free PMC article.
Point-activated ESR1Y541S has a dramatic effect on the development of sexually dimorphic organs.
Alexandra M Simond, Chen Ling, +3 authors, William J Muller.
Genes Dev, 2020 Sep 12; 34(19-20). PMID: 32912899    Free PMC article.
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Caterina Fumagalli, Alberto Ranghiero, +8 authors, Massimo Barberis.
Breast Cancer Res, 2020 Oct 17; 22(1). PMID: 33059724    Free PMC article.
XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation.
David Barua, Benazir Abbasi, Ananya Gupta, Sanjeev Gupta.
Heliyon, 2020 Oct 23; 6(10). PMID: 33088967    Free PMC article.
Comprehensive transcriptomic analysis identifies novel regulators of lung adenocarcinoma.
Amir Mokhlesi, Mahmood Talkhabi.
J Cell Commun Signal, 2020 May 18; 14(4). PMID: 32415511    Free PMC article.
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Semir Vranic, Wijendra Senarathne, +3 authors, Zoran Gatalica.
Appl Immunohistochem Mol Morphol, 2019 Sep 14; 28(9). PMID: 31517642    Free PMC article.